



## HIV and Prevention



### Funding Opportunity Announcement

Through the Corporate Grants program, Gilead intends to support the efforts of community-based organisations, healthcare providers, public health institutions and similar umbrella organisations to educate people at risk/people living with HIV about HIV prevention strategies from acquisition of the virus to the prevention of ill health and co-morbidities. HIV prevention may refer to practices that prevent the spread of HIV/AIDS or practices to protect individual or community health, or "public health policies".

### Selection Criteria

Gilead will consider a wide range of concepts that reach diverse geographic locations within Europe, Middle East and Australia (EMEA). In particular, Gilead welcomes proposals which raise awareness of and create a sense of urgency around the existing unmet needs in HIV and prevention from organisations that can demonstrate the following:

- Applicants who are able to clearly state how difficult to engage populations will be reached through clearly defined goals and milestones
- Educational concepts that could be replicated across the EMEA region, specifically how the selected proposals could be taught, adapted, and launched by other organisations
- Clear rationale on how the project will meet any unmet need in HIV prevention
- Projects that provide specific, measurable, achievable, realistic and time-sensitive objectives and action steps required to meet project goals
- Locally relevant and project specific data that supports the need for the project
- Information regarding your capacity to implement the project
- Clear details on how data will be collected and analysed and by whom

### Eligibility

Organizations must be classified as a not-for-profit and headquartered in the EMEA region with an interest in public health, including but not limited to providing health or social services, education, or advocacy for "underserved" or "hard to reach" populations. Projects should be submitted that impact more than one country across the EMEA region.

### Application Process

- Applications will be accepted from 1<sup>st</sup> November 2016 on a continual basis. Decisions are typically communicated within 12 weeks from the submission date.
- Questions about the announcement or application process should be submitted to [EMEAgrants@gilead.com](mailto:EMEAgrants@gilead.com)
- Organizations are required to submit their requests using the online application form, which can be accessed by clicking <http://www.gilead.com/responsibility/corporate-contributions/europe/europe-grant-application-process>. Please review the grant Terms and Conditions prior to submitting an application and ensure that the title used within the application begins "**FOA 1: xxx**".

### Program Specifics

- The program provides awards for a one-year period.
- Application to the EMEA Corporate Contributions program is not a promise of funding.

Gilead reserves the right to approve or disapprove any application. Award of a grant in any one year does not infer that a subsequent grant will be awarded without further application and approval.

### About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world, always keeping the patients and the communities we serve at the forefront.